Repaglinide

瑞格列奈

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRepaglinide
Drug Alias Namerepaglinida瑞格列萘利帕尼奈repaglinidumActulin +[15
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersVoltage-gated potassium channel blockers
TargetsPotassium channelVoltage-gated potassium channel
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusCystic Fibrosis
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date1997/12/22
Country/TerritoryUnited StatesTaiwanPhilippines +[13
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes MellitusCystic Fibrosis

Other Information

ATC CodeA10BX02